|
1
|
Jin KT, He KF, Teng F, Han N, Li GL, Xu ZZ
and Teng LS: Heterogeneity in primary tumors and corresponding
metastases: could it provide us with any hints to personalize
cancer therapy? Pers Med. 8:175–182. 2011. View Article : Google Scholar
|
|
2
|
Gong Y, Booser DJ and Sneige N: Comparison
of HER-2 status determined by fluorescence in situ hybridization in
primary and metastatic breast carcinoma. Cancer. 103:1763–1769.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gancberg D, Di Leo A, Cardoso F, Rouas G,
Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ and
Larsimont D: Comparison of HER-2 status between primary breast
cancer and corresponding distant metastatic sites. Ann Oncol.
13:1036–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Regitnig P, Schippinger W, Lindbauer M,
Samonigg H and Lax SF: Change of HER-2/neu status in a subset of
distant metastases from breast carcinomas. J Pathol. 203:918–926.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bozzetti C, Personeni N, Nizzoli R, Guazzi
A, Flora M, Bassano C, Negri F, Martella E, Naldi N, Franciosi V
and Cascinu S: HER-2/neu amplification by fluorescence in situ
hybridization in cytologic samples from distant metastatic sites of
breast carcinoma. Cancer. 99:310–315. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tanner M, Järvinen P and Isola J:
Amplification of HER-2/neu and topoisomerase IIalpha in primary and
metastatic breast cancer. Cancer Res. 61:5345–5348. 2001.PubMed/NCBI
|
|
7
|
Tapia C, Savic S, Wagner U, Schönegg R,
Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G,
Terracciano L, Feichter G and Bubendorf L: HER2 gene status in
primary breast cancers and matched distant metastases. Breast
Cancer Res. 9:R312007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akcakanat A, Sahin A, Shaye AN, Velasco MA
and Meric-Bernstam F: Comparison of Akt/mTOR signaling in primary
breast tumors and matched distant metastases. Cancer.
112:2352–2358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu JM, Fackler MJ, Halushka MK, Molavi DW,
Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM,
Hicks JL, Chitale D, Ladanyi M, Sukumar S and Argani P:
Heterogeneity of breast cancer metastases: comparison of
therapeutic target expression and promoter methylation between
primary tumors and their multifocal metastases. Clin Cancer Res.
14:1938–1946. 2008. View Article : Google Scholar
|
|
10
|
Baldus SE, Schaefer KL, Engers R, Hartleb
D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of
KRAS, BRAF, and PIK3CA mutations in primary colorectal
adenocarcinomas and their corresponding metastases. Clin Cancer
Res. 16:790–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Molinari F, Martin V, Saletti P, De Dosso
S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L and
Frattini M: Differing deregulation of EGFR and downstream proteins
in primary colorectal cancer and related metastatic sites may be
clinically relevant. Br J Cancer. 100:1087–1094. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scartozzi M, Bearzi I, Berardi R,
Mandolesi A, Fabris G and Cascinu S: Epidermal growth factor
receptor (EGFR) status in primary colorectal tumors does not
correlate with EGFR expression in related metastatic sites:
implications for treatment with EGFR-targeted monoclonal
antibodies. J Clin Oncol. 22:4772–4778. 2004. View Article : Google Scholar
|
|
13
|
Scartozzi M, Bearzi I, Berardi R,
Mandolesi A, Pierantoni C and Cascinu S: Epidermal growth factor
receptor (EGFR) downstream signalling pathway in primary colorectal
tumours and related metastatic sites: optimising EGFR-targeted
treatment options. Br J Cancer. 97:92–97. 2007. View Article : Google Scholar
|
|
14
|
Sasatomi E, Finkelstein SD, Woods JD,
Bakker A, Swalsky PA, Luketich JD, Fernando HC and Yousem SA:
Comparison of accumulated allele loss between primary tumor and
lymph node metastasis in stage II non-small cell lung carcinoma:
implications for the timing of lymph node metastasis and prognostic
value. Cancer Res. 62:2681–2689. 2002.PubMed/NCBI
|
|
15
|
Park S, Holmes-Tisch AJ, Cho EY, Shim YM,
Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA and Ahn MJ:
Discordance of molecular biomarkers associated with epidermal
growth factor receptor pathway between primary tumors and lymph
node metastasis in non-small cell lung cancer. J Thorac Oncol.
4:809–815. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin K, Li G, Cui B, Zhang J, Lan H, Han N,
Xie B, Cao F, He K, Wang H, Xu Z, Teng L and Zhu T: Assessment of a
novel VEGF targeted agent using patient-derived tumor tissue
xenograft models of colon carcinoma with lymphatic and hepatic
metastases. PLoS One. 6:e283842011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fichtner I, Rolff J, Soong R, Hoffmann J,
Hammer S, Sommer A, Becker M and Merk J: Establishment of
patient-derived non-small cell lung cancer xenografts as models for
the identification of predictive biomarkers. Clin Cancer Res.
14:6456–6468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin KT, He KF, Li GL and Teng LS:
Personalized cancer therapy using a patient-derived tumor tissue
xenograft model: a translational field worthy of exploring further?
Pers Med. 7:597–606. 2010. View Article : Google Scholar
|
